PT1855677E - 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses - Google Patents

3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses Download PDF

Info

Publication number
PT1855677E
PT1855677E PT06765238T PT06765238T PT1855677E PT 1855677 E PT1855677 E PT 1855677E PT 06765238 T PT06765238 T PT 06765238T PT 06765238 T PT06765238 T PT 06765238T PT 1855677 E PT1855677 E PT 1855677E
Authority
PT
Portugal
Prior art keywords
psychoses
schizophrenia
cis
treatment
dihydrotetrabanezine
Prior art date
Application number
PT06765238T
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Cambridge Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd
Publication of PT1855677E publication Critical patent/PT1855677E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT06765238T 2005-08-06 2006-08-04 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses PT1855677E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PT1855677E true PT1855677E (pt) 2009-01-13

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06765238T PT1855677E (pt) 2005-08-06 2006-08-04 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses

Country Status (20)

Country Link
US (1) US20110257220A1 (enExample)
EP (2) EP1855677B1 (enExample)
JP (1) JP2009504622A (enExample)
KR (1) KR20080033500A (enExample)
AT (2) ATE534391T1 (enExample)
AU (1) AU2006277753B2 (enExample)
CA (1) CA2620960A1 (enExample)
CY (1) CY1108843T1 (enExample)
DE (1) DE602006004009D1 (enExample)
DK (1) DK1855677T3 (enExample)
ES (1) ES2318771T3 (enExample)
HR (1) HRP20090074T3 (enExample)
MX (1) MX2008001549A (enExample)
NZ (1) NZ566011A (enExample)
PL (1) PL1855677T3 (enExample)
PT (1) PT1855677E (enExample)
RS (1) RS50807B (enExample)
RU (1) RU2407743C2 (enExample)
SI (1) SI1855677T1 (enExample)
WO (1) WO2007017654A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
JP2013527237A (ja) 2010-06-01 2013-06-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド ベンゾキノロン系vmat2阻害剤
US9658363B2 (en) 2011-04-01 2017-05-23 3M Innovative Properties Company Films including triazine-based ultraviolet absorbers
EP3099299A4 (en) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
EP3548027A1 (en) * 2016-12-02 2019-10-09 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
EA202090676A1 (ru) 2017-01-27 2021-10-08 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
IL273300B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
RU2407743C2 (ru) 2010-12-27
SI1855677T1 (sl) 2009-04-30
ATE534391T1 (de) 2011-12-15
AU2006277753A1 (en) 2007-02-15
KR20080033500A (ko) 2008-04-16
DE602006004009D1 (de) 2009-01-15
JP2009504622A (ja) 2009-02-05
HK1111083A1 (en) 2008-08-01
US20110257220A1 (en) 2011-10-20
EP1855677B1 (en) 2008-12-03
ATE415968T1 (de) 2008-12-15
DK1855677T3 (da) 2009-02-09
CA2620960A1 (en) 2007-02-15
EP2050451A1 (en) 2009-04-22
CY1108843T1 (el) 2014-07-02
WO2007017654A1 (en) 2007-02-15
RU2008108623A (ru) 2009-09-20
PL1855677T3 (pl) 2009-07-31
EP1855677A1 (en) 2007-11-21
RS50807B (sr) 2010-08-31
AU2006277753B2 (en) 2011-11-10
HRP20090074T3 (en) 2009-04-30
NZ566011A (en) 2011-01-28
MX2008001549A (es) 2008-04-04
ES2318771T3 (es) 2009-05-01
EP2050451B1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
PT1855677E (pt) 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
IL173002A (en) Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis
ZA200604114B (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
PL1799231T3 (pl) Zastosowanie cyklodekstryny do leczenia i zapobiegania chorobom zapalnym oskrzeli
ZA200801171B (en) 3, IIB-CIS-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
IL186676A0 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
IL186831A0 (en) 4-phenyl- 5-oxo - 1,4,5,6,7,8 - hexahydroquinoline derivatives as medicaments for the treatment of infertility
IL186672A0 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PL1881830T3 (pl) Pochodne 4-fenylo-5-okso-1,4,5,6,7,8-heksahydrochinoliny do leczenia niepłodności
ZA200800999B (en) Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
TW200714284A (en) Novel method
GB0513835D0 (en) HIV inhibitors
ZA200803101B (en) 4-oxadiozolyl-piperidine compounds and use thereof
HK1117520A (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
WO2007006548A3 (de) Antibakterielle amid-makrozyklen vii
AP2005003270A0 (en) Composition for the treatment of humans.